DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.

Abstract

AIM To characterize the pharmacodynamic profile of DA-1229, a novel dipeptidyl peptidase (DPP) 4 inhibitor. MAIN METHODS Enzyme inhibition assays against DPP4, DPP8 and DPP9. Antidiabetic effects of DA-1229 in HF-DIO mice and young db/db mice. KEY FINDINGS DA-1229 was shown to potently inhibit the DPP4 enzyme in human and murine soluble forms and the… (More)
DOI: 10.1016/j.lfs.2011.10.007

6 Figures and Tables

Topics

  • Presentations referencing similar topics